Immunotherapy's Expanding Role: From Advanced to Early-Stage Cancer

Immunotherapy, previously a treatment for advanced, inoperable cancer, is now seeing increased use in earlier stages, both before (neoadjuvant) and after (adjuvant) surgery.

Researchers have summarized findings from studies across seven tumor areas: skin, lung, breast, gastrointestinal, gynecological, head and neck, and urological cancers.

Key Findings

• Adjuvant immunotherapy administered post-surgery has demonstrated a reduction in the risk of disease recurrence.
• Neoadjuvant treatment, given while a tumor is still present, can enhance the immune system's ability to identify tumor cells.
• Results across several tumor areas suggest that combined neoadjuvant and adjuvant immunotherapy may offer advantages over adjuvant treatment alone.

Important Considerations

The review highlights that results vary significantly among different cancer types.

Challenges associated with the treatment include the potential for side effects and the risk of overtreatment in patients who might have been sufficiently treated with surgery alone.